MRZM - Marizyme appoints new CEO

The development-stage biotech company, Marizyme (OTCQB:MRZM +12.8%), has named David Barthel as its new chief executive officer. The appointment comes more than seven months after the company disclosed the resignation of former CEO Neil Campbell. Mr. Barthel most recently led Health Logic Interactive and its fully-owned subsidiary, My Health Logic. Previously, having founded The SmartPill Corp, he has led the company through multiple funding rounds, raising over $70 million until it was acquired by Medtronic (NYSE:MDT). At Marizyme (OTCQB:MRZM), Mr. Barthel will spearhead the company’s efforts in submitting regulatory filings to the FDA for DuraGraft and MATLOC 1. He will also be tasked with reinforcing the financials position of the company ahead of a potential Nasdaq listing in 2022. As of June 2021, Marizyme (OTCQB:MRZM) reported $2,104 in cash compared to $2.9M at the end of 2020.

For further details see:

Marizyme appoints new CEO